Drug Profile
Lintuzumab
Alternative Names: Anti-CD33 MAb; HuM 195; SGN-33Latest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator PDL BioPharma
- Developer Seattle Genetics
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD33 antigen inhibitors; Cytokine inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Myelodysplastic syndromes